Sugi Predict

Sugi Predict / Compounds / SCHEMBL4920503

SCHEMBL4920503

SCHEMBL4920503

O=C(CCC(C(=O)O)N1C(=O)c2ccccc2C1=O)OCc1ccccc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.66
▸ POLB P06746 4/20 0.66
▸ MAPK1 P28482 2/20 0.66
▸ KDM4E B2RXH2 1/20 0.66
▸ TP53 P04637 1/20 0.66
▸ GLA P06280 1/20 0.66
▸ CYP3A4 P08684 1/20 0.66
▸ CYP2D6 P10635 1/20 0.66
▸ HPGD P15428 1/20 0.66
▸ ALOX12 P18054 1/20 0.66
▸ NFKB1 P19838 1/20 0.66
▸ APEX1 P27695 1/20 0.66
▸ HSD17B10 Q99714 1/20 0.66
▸ GAA P10253 2/20 0.59
▸ KMT2A Q03164 2/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ L3MBTL1 Q9Y468 3/20 0.50
▸ AADAT Q8N5Z0 1/20 0.48
▸ CDC25B P30305 1/20 0.48
▸ TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1329008 1.00 ALDH1A1 (0.66) ALDH1A1POLBMAPK1KDM4ETP53
SCHEMBL7617995 0.90 ALDH1A1 (0.52) ALDH1A1POLBMAPK1KDM4ETP53
SCHEMBL73667 0.86 ALDH1A1 (0.62) ALDH1A1POLBMAPK1KDM4ETP53
SCHEMBL76879 0.86 ALDH1A1 (0.62) ALDH1A1POLBMAPK1KDM4ETP53
SCHEMBL73666 0.86 ALDH1A1 (0.62) ALDH1A1POLBMAPK1KDM4ETP53
SCHEMBL4915153 0.85 ALDH1A1 (0.68) ALDH1A1POLBMAPK1KDM4ETP53
SCHEMBL4906389 0.85 ALDH1A1 (0.68) ALDH1A1POLBMAPK1KDM4ETP53
SCHEMBL2992788 0.83 POLB (0.73) ALDH1A1POLBMAPK1KDM4ETP53
SCHEMBL4915146 0.82 POLB (0.71) ALDH1A1POLBMAPK1KDM4ETP53
SCHEMBL29036213 0.82 POLB (0.71) ALDH1A1POLBMAPK1KDM4ETP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101993408-B Method for preparing 2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl) glutaric acid-5-benzyl ester SINOCHEM CORP 2012-11-07 — — CN disclosed
CN-101993408-B Method for preparing 2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl) glutaric acid-5-benzyl ester SINOCHEM CORP 2012-11-07 — — CN disclosed
CN-101193908-B Organic compounds NOVARTIS AG 2012-04-11 — — CN disclosed
CN-101993408-A Method for preparing 2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl) glutaric acid-5-benzyl ester SINOCHEM CORP 2011-03-30 — — CN disclosed
CN-101993408-A Method for preparing 2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl) glutaric acid-5-benzyl ester SINOCHEM CORP 2011-03-30 — — CN disclosed
US-20080234508-A1 Process for the Preparation of N(5)-Ethylglutamine DONGBU FINE CHEMICALS CO., LTD (KR) 2008-09-25 — — US disclosed
WO-2006123909-A1 PROCESS FOR THE PREPARATION OF N(5)-ETHYLGLUTAMINE DONGBU FINE CHEMICALS CO., LTD. (KR) 2006-11-23 — — WO disclosed
EP-1062210-B1 1,2-DIAZEPANE DERIVATIVES AS INTERLEUKIN-1BETA CONVERTING ENZYME INHIBITORS VERTEX PHARMA (US) 2005-06-01 — — EP disclosed
EP-0629627-B1 Bicyclic carboxylic acids and their derivatives as nep and aca inhibitors BRISTOL MYERS SQUIBB CO (US) 2004-05-06 — — EP disclosed
US-6426413-B1 SUCH AS (N-BENZYLOXYCARBONYL-HYDRAZINO)-ACETIC ACID TERT-BUTYL ESTER; FOR PREVENTING AND TREATING INTERLEUKIN-MEDIATED DISEASES, APOPTOSIS, AUTOIMMUNE DISEASES, BONE DISORDERS, PROLIFERATIVE DISORDERS, INFECTIONS, AND DEGENERATIVE DISEASES VERTEX PHARMACEUTICALS INCORPORATED 2002-07-30 — — US disclosed
US-5723602-A ANGIOTENSIN CONVERTING ENZYME AND ENDOPEPTIDASE INHIBITORS, CARDIOVASCULAR DISORDERS E. R. SQUIBB & SONS, INC. (US) 1998-03-03 — — US disclosed
US-5672599-A DUAL ACTION ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND NEUTRAL ENDOPEPTIDASE INHIBITORS; TREATMENT OF CARDIOVASCULAR DISORDERS BRISTOL-MYERS SQUIBB CO. (US) 1997-09-30 — — US disclosed
US-5670699-A Process for preparing amino acid esters useful as intermediates for compounds containing a fused bicyclic ring BRISTOL-MYERS SQUIBB CO. (US) 1997-09-23 — — US disclosed
US-5654294-A CARDIOVASCULAR DISORDERS BRISTOL-MYERS SQUIBB (US) 1997-08-05 — — US disclosed
US-5646276-A ANGIOTENSIN CONVERTING ENZYME AND NEUTRAL ENDOPEPTIDASE INHIBITORS; CARDIOVASCULAR DISORDERS BRISTOL-MYERS SQUIBB CO. (US) 1997-07-08 — — US disclosed
US-5627278-A MULTISTAGE REACTION FORMED BY AMIDATION, COUPLING AND REDUCTION BRISTOL-MYERS SQUIBB CO. (US) 1997-05-06 — — US disclosed
US-5616775-A ESTERIFYING A N-PROTECTED METHIONINE; OXIDIZING; REACTING WITH AN ACID ANHYDRIDE THEN AN ALKALI METAL HYDROXIDE BRISTOL-MYERS SQUIBB CO. (US) 1997-04-01 — — US disclosed
US-5552397-A HYPOTENSIVE AGENTS E. R. SQUIBB & SONS, INC. (US) 1996-09-03 — — US disclosed
US-5508272-A SELECTIVE ACE INHIBITORS, HYPOTENSIVE AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 1996-04-16 — — US disclosed
EP-0629627-A2 Bicyclic carboxylic acids and their derivatives as nep and aca inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 1994-12-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234508-A1 Process for the Preparation of N(5)-Ethylglutamine GLUL, PGA5, GRIK5 ALDH1A1 1683/4885POLB 2896/4885MAPK1 3138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.